Jan 15, 2020
The Malignant Pleural Mesothelioma Market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy, which have shown promising anticancer activity against mesothelioma in recent clinical trials. These drugs have been approved for other indications and now are being used in mono...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper